Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medication Abortion Mifepristone Protections topic
No spam. Unsubscribe anytime.
AB 260 would protect access to medication abortion and shield providers in California amid federal uncertainty
Summary
AB 260 (labeled AB 2 60 in testimony) would protect access to mifepristone and other medication‑abortion services in California, shield clinicians and pharmacists from disciplinary action for providing medication abortion, allow removal of provider names from prescription labels, and expand telehealth access for medication abortion.
Majority Leader presented AB 260 as a measure to "protect safe and legal reproductive health care here in California," emphasizing concern about recent federal actions that could limit access to medication abortion. The bill specifically targets statutory protections for the medication mifepristone, shielding clinicians and pharmacists from licensing or disciplinary penalties when they legally provide the medication, enabling certain privacy protections for prescribers, requiring continued health‑plan coverage for medication abortion, and expanding telehealth access.
Dr. Kelly Pfeiffer, a family medicine physician who runs medication‑abortion clinics that serve out‑of‑state patients, said, "AB 260 will help by protecting access to the medications we use for abortion. This bill will allow us to continue to treat our patients even if politicians in Washington act against the science to further limit mifepristone." Pfeiffer described telehealth provision and mail delivery of medication abortion as safe, evidence‑based practice used for years.
Miranda Pond of Reproductive Freedom For All California, a cosponsor, told the committee the bill "guarantees that our state will not allow political interference to roll back the access to safe, effective medication abortion" and protects telehealth access for rural and underserved communities.
Supporters included Planned Parenthood Affiliates of California and physician groups. The attorney general's office and multiple statewide elected officials were listed among cosponsors on the record.
Committee business shows the bill was moved by Senator Richardson and referred to the committees listed on the motion. The transcript contains multiple roll‑call and "on call" entries; a later clerk announcement recorded a reported final vote count as 6 yes, 6 no and 1 abstention (transcript language: "6 to 6 to 1"). The committee record in the hearing shows the motion was made and the bill was set to be referred to Business and Professions and Economic Development (per the motion record earlier in the hearing).
Why it matters: supporters said AB 260 protects clinical access to medication abortion and protects clinicians and pharmacists from regulatory consequences if federal actions restrict mifepristone. Opponents were not recorded in detail in this hearing; sponsors emphasized the bill's telehealth and patient‑privacy components.
Next steps: the bill was referred to the committees listed in the motion; sponsors and cosponsors encouraged continued outreach as the bill proceeds through its legislative path.
